🔬 Biopsy smart, not routine.
Knowing when to biopsy—and when not to— can change diagnosis, management, and outcomes in upper GI endoscopy.
From Barrett’s protocols to linitis plastica sampling—precision matters.
#GastroAGI #Endoscopy #UpperGI #Biopsy #Gastroenterology #GIEndoscopy #MedicalEducation
🎯 HCC treatment is evolving…
TACE + immunotherapy + targeted therapy shows stronger outcomes—but are we ready to change practice?
⚠️ Promising data, but guidelines still need phase III confirmation
#GastroAGI #HCC #LiverCancer #TACE #Immunotherapy #TargetedTherapy #Hepatology #Oncology #MedEd
CT chest shows a markedly dilated, fluid-filled oesophagus with smooth distal tapering and no obstructing mass—imaging features suggestive of achalasia.
Diagnosis confirmed on high-resolution manometry (Type II).
Patient underwent POEM, with dysphagia score improving
from 3 → 1.
📌 A nice example of radiology–manometry–endoscopy concordance and clinical response.
Nutrition is central in cirrhosis care. Malnutrition, sarcopenia, and frailty worsen transplant outcomes.
Early assessment, adequate calories, and high-quality protein prehabilitation preserve muscle and resilience. The waitlist is a window to intervene.
#Cirrhosis #Hepatology #TransplantMedicine #NutritionInCirrhosis #Sarcopenia #MedicalEducation #EvidenceBasedMedicine #GastroAGI
GastroAGI is an AI-powered knowledge platform for gastroenterology & hepatology—built for clinicians, trainees, and researchers.
Evidence-first answers from journals, guidelines, and conferences. No noise. No hallucinations. Just clarity.
#GastroAGI #Gastroenterology #Hepatology #MedicalAI #EvidenceBasedMedicine #MedEd #ClinicalPractice #GIResearch
miR147 protects gut mucosa by strengthening epithelial integrity and controlling inflammation.
Knockout → severe colitis, barrier loss, ↑ permeability.
miR147 targets Ndufa4 to maintain metabolic balance + type I IFN signaling.
Therapeutic potential in IBD & colorectal cancer.
COBALT Trial (PBC): Despite early termination, adjusted analyses + real-world external controls showed obeticholic acid (OCA) reduces major liver events.
EC (External Control) analysis: 60% risk reduction in the risk of adverse clinical outcomes like death, liver transplantation, or hepatic decompensation.(HR 0.39).
Well-tolerated; pruritus most common.
Highlights power of hybrid RCT + real-world evidence.
A new SVM-based machine-learning model accurately predicts postoperative recurrence in ESCC.
Using factors like age, ECOG, NLR, CPR, CY211, TNM stage & complications, the SVM6+8 model reached 94% sensitivity.
A nomogram predicts 1-, 3-, 5-yr DFS, helping identify high- vs low-risk patients.
Enables personalized follow-up & adjuvant therapy.
Exercise boosts anticancer immunity through the gut microbiome.
(Gastroenterology, Feb 2026)
In resistant tumor models, exercise reshaped microbial metabolism to increase formate, a postbiotic that enhanced CD8 T-cell cytotoxicity via Nrf2 activation, improving antitumor immunity and immunotherapy response.
#GastroAGI #GIOncology #CancerImmunotherapy #GutMicrobiome #ASCO #Gastroenterology
GastroAGI